TScan Therapeutics Inc - fluxo de caixa trimestral (NASDAQ:TCRX) | MetaTrader

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Cash from operating activities -27.41 M-37.59 M-33.27 M-32.46 M-32 M -135.32 M Cash from investing activities 27.29 M13.53 M48.44 M32.58 M14.83 M 109.37 M Cash from financing activities 45.69 M-525 K116 K073 K -336 K Free cash flow -28.3 M-39.12 M-34.55 M-33.89 M-32.17 M -139.73 M

Notícias

H.C. Wainwright reitera recomendação de compra para Tscan com preço-alvo de US$ 7

TScan Therapeutics anuncia renúncia do vice-presidente de finanças

Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com

Lucro da Tscan Therapeutics superou projeções por $0,09; receita supera estimativas

Tscan Therapeutics earnings beat by $0.09, revenue topped estimates

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan completes enrollment in trial cohort, receives FDA clearance

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)